Free Trial

Crescent Biopharma (CBIO) SEC Filings & 10K Form

Crescent Biopharma logo
$15.09 -0.20 (-1.31%)
As of 04:00 PM Eastern

Recent Crescent Biopharma SEC Filings

DateFilerForm TypeView
06/23/2025
5:48 PM
Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
5:51 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Moran Susan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
5:32 PM
Fairmount Funds Management LLC (Filed by)
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form SCHEDULE 13D
06/23/2025
5:41 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Lubner David Charles (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
5:43 PM
Balcom Alexandra (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
5:46 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Violin Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
5:22 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Moran Susan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:23 PM
Balcom Alexandra (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:23 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Violin Jonathan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:24 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Lubner David Charles (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:25 PM
Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:26 PM
Brumm Joshua T (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:27 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
McNeill Jonathan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:28 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Scalzo Richard William (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:29 PM
Doughty Christopher Grant (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
5:29 PM
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Lynch Ryan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/23/2025
3:30 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SCHEDULE 13G
06/18/2025
4:28 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2025
5:53 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025
7:30 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/30/2025
7:30 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/30/2025
7:30 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
05/29/2025
7:30 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
05/14/2025
11:15 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form EFFECT
05/14/2025
4:06 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2025
3:39 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 424B3
05/12/2025
6:12 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form S-4/A
04/28/2025
7:00 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2025
7:01 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
04/28/2025
7:17 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form S-4/A
04/28/2025
7:00 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
04/04/2025
12:29 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form S-4/A
04/03/2025
6:30 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
04/03/2025
6:30 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
02/28/2025
4:05 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
02/27/2025
5:01 AM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Form 425
02/14/2025
5:38 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SCHEDULE 13G/A
01/31/2025
4:00 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
8:00 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
8:00 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form DEFA14A
12/26/2024
3:30 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad)

Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.

This little-known company holds nearly 100 patents and trades for around $7
11/27/2024
1:22 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Logos Global Management LP (Filed by)
Form SC 13G
11/13/2024
3:30 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2024
3:42 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/07/2024
3:47 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form DEFA14A
11/06/2024
4:41 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G
11/04/2024
1:01 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Weinstein Benjamin (Filed by)
Form SCHEDULE 13G/A
10/29/2024
7:09 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/29/2024
7:09 AM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form DEFA14A
08/15/2024
4:01 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Invus Global Management, LLC (Filed by)
Form SC 13G/A
08/09/2024
3:30 PM
DEBBANE RAYMOND (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Invus Global Management, LLC (Reporting)
Invus Public Equities Advisors, LLC (Reporting)
Invus Public Equities, L.P. (Reporting)
Siren, L.L.C. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2024
3:30 PM
DEBBANE RAYMOND (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Invus Global Management, LLC (Reporting)
Invus Public Equities Advisors, LLC (Reporting)
Invus Public Equities, L.P. (Reporting)
Siren, L.L.C. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2024
4:16 PM
DEBBANE RAYMOND (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Invus Global Management, LLC (Reporting)
Invus Public Equities Advisors, LLC (Reporting)
Invus Public Equities, L.P. (Reporting)
Siren, L.L.C. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2024
2:55 PM
Crescent Biopharma (Filer)
GLYCOMIMETICS INC (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2024
6:24 PM
Crescent Biopharma (Subject)
GLYCOMIMETICS INC (Subject)
Invus Global Management, LLC (Filed by)
Form SC 13G/A
07/29/2024
4:55 PM
DEBBANE RAYMOND (Reporting)
Crescent Biopharma (Issuer)
GLYCOMIMETICS INC (Issuer)
Invus Global Management, LLC (Reporting)
Siren, L.L.C. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CBIO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners